Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 18 May 2017

PCI Biotech to present at Bio€quity Europe

PCI Biotech Holding    

Published: 12:00 CEST 18-05-2017 /GlobeNewswire /Source: PCI Biotech Holding / : PCIB /ISIN: N00010405640

PCI Biotech to present at Bio€quity Europe

Oslo, Norway, May 18, 2017 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present the Company at Bio€quity Europe, an investor and partnering event.

The event is taking place at Paris Marriot Rive Gauche Conference Center, France, 22-23 May 2017. Dr. Per Walday, CEO, will present an overview of PCI Biotech's technology and the multiple business development and commercial opportunities available based on this proprietary platform on Tuesday 23 May at 09:00am (CEST).

The presentation will be made available on PCI Biotech's website (www.pcibiotech.com ) under News.

About PCI Biotech         
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

 

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead fimaChem programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.


Contact information:   
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com      
Ronny Skuggedal, CFO, rs@pcibiotech.com , Mobile: +47 9400 5757.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: PCI Biotech Holding ASA, Ullernchausséen 64, Oslo 0379, Norway
If you would like to unsubscribe and stop receiving these e-mails click here.